Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
3510.00 | 15,113 Cr | 41.53 | 3.99 | 0.57 | 9.90 | 13.43 | 4.93 | |
410.75 | 14,894 Cr | 39.50 | 2.61 | 0.24 | 5.09 | 5.85 | 3.23 | |
1376.30 | 14,268 Cr | 32.21 | 4.86 | 0.55 | 14.85 | 19.95 | 13.41 | |
1244.80 | 14,172 Cr | 82.15 | 4.43 | 0.06 | 4.73 | 9.37 | 4.06 | |
4284.00 | 13,092 Cr | 33.11 | 5.28 | 0.26 | 16.37 | 21.90 | 14.91 | |
915.20 | 12,170 Cr | 56.26 | 5.23 | 0.00 | 8.36 | 10.91 | 7.57 | |
2840.35 | 11,130 Cr | 36.94 | 8.98 | 0.18 | 21.52 | 19.32 | 9.69 |
Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,246.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers. Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility. Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk. The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials. Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹688.00 and a high of ₹1,405.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anupam Rasayan India Ltd has a market capitalization of approximately 14,171.84. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 82.15 and operates in the Chemicals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,171.84 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anupam Rasayan India Ltd operates in the Chemicals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 82.15. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Anupam Rasayan is acquiring 100% of Doriath S.à r.l. and 15% of Batam S.à r.l., both of which are based in Luxembourg.
Anupam Rasayan India Limited has scheduled its next board meeting for February 14, 2026.
The 10,000 crore Biopharma Shakti scheme promotes domestic production of biologics and biosimilars, which increases demand for the pharmaceutical intermediates and key starting materials (KSMs) manufactured by Anupam Rasayan.
Bearish
2
Neutral
6
Bullish
6
Bearish
21
Neutral
6
Bullish
19
Bearish
19
Neutral
0
Bullish
13
Merger/Acquisition
Anupam Rasayan has closed the purchase of 100% of Jayhawk Fine Chemicals for ~US$150m via subsidiary Doriath S.à r.l., financed by an Oaktree affiliate (Altis XII) and Axis Bank; Jayhawk will be fully consolidated and EPS-accretive.
Merger/Acquisition
Anupam Rasayan India Ltd completed the acquisition of Monitchem Kansas S.à r.l. and its subsidiaries (Kansas HoldCo Inc., Kansas HoldCo 1, Inc., Jayhawk Fine Chemicals) through its wholly‑owned subsidiary Doriath on 27 Feb 2026.
Encumbrance Release
Promoter Anand Sureshbhai Desai released pledge on 42,49,220 equity shares (3.73% of share capital) of Anupam Rasayan India Ltd on 26-Feb-2026; pledge was with Catalyst Trusteeship Ltd on behalf of Standard Chartered Capital Ltd. and Aditya Birla Capital.
Encumbrance Disclosure
Rehash Industrial and Resins Chemicals Pvt Ltd (promoter) created a pledge of 5,000,000 equity shares (4.39% of Anupam Rasayan) in favor of TATA Capital Ltd to avail a loan (creation date 17‑Feb‑2026; disclosed 26‑Feb‑2026).
Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers.
Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility.
Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk.
The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials.
Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.
Chemicals
Chemicals - Speciality - Large
14,172 Cr
Low Risk
82.1
42.6
2.9
4.4
1,405.00
688.00
Sales CAGR
Profit CAGR
ROE
ROCE
